SCHEMBL1385016

SCHEMBL1385016

O=C(O)C1CCCCN1S(=O)(=O)c1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.72
HTT P42858 1/20 0.72
LMNA P02545 2/20 0.61
MAPT P10636 2/20 0.61
NPSR1 Q6W5P4 1/20 0.61
FKBP1A P62942 3/20 0.60
CYP3A4 P08684 1/20 0.58
CYP2C19 P33261 1/20 0.58
RAB9A P51151 1/20 0.58
MMP2 P08253 1/20 0.57
MMP9 P14780 1/20 0.57
PKM P14618 1/20 0.56
GHSR Q92847 3/20 0.55
USP2 O75604 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2977278 1.00 ALDH1A1 (0.72) ALDH1A1HTTLMNAMAPTNPSR1
SCHEMBL6997 0.95 ALDH1A1 (0.65) ALDH1A1HTTLMNAMAPTNPSR1
SCHEMBL23519421 0.95 ALDH1A1 (0.65) ALDH1A1HTTLMNAMAPTNPSR1
SCHEMBL6996 0.95 ALDH1A1 (0.65) ALDH1A1HTTLMNAMAPTNPSR1
Water SCHEMBL28790504 0.94 ALDH1A1 (0.63) ALDH1A1HTTLMNAMAPTNPSR1
SCHEMBL7995082 0.91 MMP2 (0.70) ALDH1A1HTTLMNAMAPTNPSR1
SCHEMBL7995079 0.91 MMP2 (0.70) ALDH1A1HTTLMNAMAPTNPSR1
SCHEMBL5702097 0.90 ALDH1A1 (0.58) ALDH1A1HTTLMNAMAPTNPSR1
SCHEMBL21519741 0.90 ALDH1A1 (0.58) ALDH1A1HTTLMNAMAPTNPSR1
SCHEMBL5702286 0.90 ALDH1A1 (0.58) ALDH1A1HTTLMNAMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4812758-B2 2011-11-09 JP claimed
US-7777042-B2 N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof AVENTIS PHARMACEUTICALS INC. (US) 2010-08-17 US claimed
US-20080139556-A1 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2008-06-12 US claimed
EP-1778637-A2 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF Aventis Pharmaceuticals, Inc. (US) 2007-05-02 EP claimed
WO-2006012256-A2 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2006-02-02 WO claimed
US-20260144730-A1 COMPOSITION FOR SKIN ANTI-AGING, SKIN BRIGHTENING OR SKIN REVERSE-AGING CONTAINING AMIDE-BASED COMPOUND AMOREPACIFIC CORPORATION (KR) 2026-05-28 US disclosed
US-20260083715-A1 COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND AMOREPACIFIC CORPORATION (KR) 2026-03-26 US disclosed
EP-4692062-A1 NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME Amorepacific Corporation (KR) 2026-02-11 EP disclosed
WO-2024205303-A1 NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME (주)아모레퍼시픽 2024-10-03 WO disclosed
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS PLIANT THERAPEUTICS INC (US) 2024-08-15 US disclosed
US-11952376-B2 Substituted amino acids as integrin inhibitors PLIANT THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
US-20220144829-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2022-05-12 US disclosed
US-11180494-B2 Substituted amino acids as integrin inhibitors PLIANT THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
CN-113195053-A Amino acid compounds and methods of use 普利安特治疗公司 2021-07-30 CN disclosed
US-20200109141-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2020-04-09 US disclosed
US-7777042-B2 N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof AVENTIS PHARMACEUTICALS INC. (US) 2010-08-17 US disclosed
US-20080139556-A1 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2008-06-12 US disclosed
EP-1778637-A2 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF Aventis Pharmaceuticals, Inc. (US) 2007-05-02 EP disclosed
WO-2006012256-A2 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144730-A1 COMPOSITION FOR SKIN ANTI-AGING, SKIN BRIGHTENING OR SKIN REVERSE-AGING CONTAINING AMIDE-BASED COMPOUND TYR, ATG13, ARGLU1 ALDH1A1 1443/4885HTT 1805/4885LMNA 147/4885
US-20220144829-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA1, ITGAL ALDH1A1 1981/4885HTT 4656/4885LMNA 1922/4885
US-20260083715-A1 COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND ARG1, MSR1, TLR1 ALDH1A1 3501/4885HTT 4042/4885LMNA 3265/4885
US-20200109141-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA1, ITGAL ALDH1A1 1981/4885HTT 4656/4885LMNA 1922/4885
US-11952376-B2 Substituted amino acids as integrin inhibitors ITGB6, ITGA1, ITGB1 ALDH1A1 2168/4885HTT 4639/4885LMNA 2121/4885
US-11180494-B2 Substituted amino acids as integrin inhibitors ITGB6, ITGA1, ITGB1 ALDH1A1 2168/4885HTT 4639/4885LMNA 2121/4885
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS ITGB6, ITGA1, ITGB1 ALDH1A1 2168/4885HTT 4639/4885LMNA 2121/4885
US-20080139556-A1 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF FKBP1A, FKBP1B, FKBP3 ALDH1A1 3038/4885HTT 535/4885LMNA 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.